Collectively, these findings indicate that epigenetic methylation of MXD3 in cancer patients is associated with dysfunctional T-cell phenotypes via different mechanisms that ultimately result in poor prognoses of melanoma, leukemia, breast, glioma, and kidney cancer cohorts while prolonging the survival of endometrial cancer cohorts. The gene discussed is MXD3; the disease is leukemia.